Co-administration of Trelegy Ellipta with budesonide (Pulmicort) and albuterol
Trelegy Ellipta contains an inhaled corticosteroid (fluticasone furoate), a long-acting muscarinic antagonist (umeclidinium), and a long-acting β2-agonist (vilanterol). [1]
Because Trelegy already includes an inhaled corticosteroid, adding Pulmicort increases inhaled corticosteroid exposure. [1]
Albuterol is an appropriate short-acting β2-agonist for acute symptom relief while on Trelegy. [1]
Medication Selection Algorithm
- Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is used as maintenance therapy for COPD or asthma. [1]
- Pulmicort (budesonide) is an additional inhaled corticosteroid and duplicates the inhaled corticosteroid component already present in Trelegy. [1]
- Albuterol (short-acting β2-agonist) is used for symptomatic relief of acute bronchospasm symptoms. [1]
Safety Considerations for Adding Pulmicort to Trelegy
- Trelegy carries warnings for hypercorticism and adrenal suppression from inhaled fluticasone exposure, particularly with exceeding the recommended dosage or in sensitive patients. [1]
- Systemic corticosteroid effects can occur rarely in sensitive patients, and reducing inhaled corticosteroid dose may be required if systemic effects develop. [1]
- Combining two inhaled corticosteroids increases the likelihood of inhaled corticosteroid overexposure. [1]
Use of Albuterol (Short-Acting β2-Agonist) with Trelegy
- Trelegy is not indicated for relief of acute bronchospasm. [1]
- Acute symptoms should be treated with an inhaled short-acting β2-agonist such as albuterol. [1]
- Excessive use of short-acting β2-agonists is a marker of worsening disease and should prompt reevaluation of the overall regimen. [1]
- Trelegy dosing should not be increased to treat acute symptoms. [1]
Treatment Appropriateness Depends on Underlying Diagnosis
- If the indication is COPD maintenance therapy, Trelegy is the maintenance regimen, and adding an extra inhaled corticosteroid (Pulmicort) increases cumulative ICS exposure beyond the single-ICS component already in Trelegy. [1]
- If the indication is asthma maintenance therapy, Trelegy is still a maintenance regimen and albuterol is the recommended short-acting bronchodilator for acute symptoms. [1]
- For asthma, the guideline approach uses an ICS-containing controller with a short-acting β2-agonist as the reliever rather than relying on the long-acting controller inhaler for acute relief. [2]
Common Pitfalls to Avoid
- Using Trelegy as a rescue medication for acute bronchospasm is not indicated and is not studied for rescue use. [1]
- Using additional LABA-containing therapy with Trelegy increases the risk of overdose because Trelegy already contains a LABA (vilanterol). [1]
- Adding a second inhaled corticosteroid without a prescriber-directed plan increases the risk of systemic corticosteroid effects in susceptible patients. [1]
Clinical Action Needed
Clinician-directed confirmation of the asthma vs COPD diagnosis and the rationale for adding Pulmicort is required before co-prescribing Pulmicort with Trelegy. [1]
Albuterol can be continued as the short-acting reliever for acute symptoms while on Trelegy when prescribed as part of the regimen. [1]